Director

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Institution	Shares	Value	Change
Vanguard	8,139,579	$1.4B	DECREASED
Capital Group	7,483,866	$1.3B	DECREASED
BlackRock	4,419,366	$745M	INCREASED
FMR	4,060,032	$685M	INCREASED
Goldman Sachs	3,372,760	$569M	INCREASED

Align Technology Inc (ALGN) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades